Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being.

Psilocybin, a psychedelic drug, is being studied for medicinal use, particularly in adult psychiatry and palliative care. Clinical trials show it may benefit patients with treatment-resistant depression and those in palliative care, often in specialist centers. It acts rapidly by targeting the 5HT2A receptor. Its psychoactive effects are well documented, but their clinical importance is debated. Many questions remain about its efficacy for other conditions and its role in psychotherapy.

Study at a glance

Abstract

Although long known for their psychoactive effects, psychedelic drugs have only recently been investigated for medicinal use. Psilocybin has attracted the greatest interest with studies suggesting that it may be a useful agent in psychiatry and in palliative care. Clinical trials that included psilocybin were searched in PubMed, Embase, and ClinicalTrials.gov, demonstrating that adult psychiatry and palliative care are the medical fields that show the greatest interest in psilocybin treatment. Psilocybin is a powerful drug that needs to be used with caution but may benefit some patients, including when other options have failed. It is best evidenced in treatment resistant depression and in palliative care, where patients are usually treated in specialist care centers. It has a novel mechanism of action, targeting the 5HT2A receptor, and can show rapid onset of action. There are many questions regarding its use that remain to be clarified, including its efficacy for other indications and its role as adjunctive treatment in psychotherapy. The psychoactive, or psychedelic effects are well documented, but their clinical importance is disputed.